埃沃格利普丁对大动脉膜化的进展的影响
Jae-Kwan Song1, Sahmin Lee1, Yong-Jin Kim2
1Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
在96周的甲状腺狭窄症患者中,Evogliptin并没有显著降低大动脉结石化进展. 然而,它显示出抑制化的趋势,因此在更大的试验中需要进一步调查.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 对大动脉狭窄症 (AS) 的医学治疗仍然是一个重大的临床挑战.
- 了解AS的进展和确定有效的治疗方法至关重要.
研究的目的:
- 为了评估埃沃格利普丁 (evogliptin) - - 一种二二基化酶-4抑制剂 - - 在减缓大动脉狭窄症进展方面的疗效.
- 评估埃沃格利普丁对大动脉结石体积 (AVCV) 和活性结石化的影响.
主要方法:
- 这是一项随机,双盲,安慰剂控制的研究,涉及228名AS患者.
- 患者接受了安慰剂,5毫克埃沃格利普丁或10毫克埃沃格利普丁,持续96周.
- 主要终点:通过计算机断层扫描对AVCV的96周变化;次要终点:通过18F-NaF PET对活性化的48周变化.
主要成果:
- 在evogliptin组和安慰剂组之间,在96周的AVCV变化中没有显著差异.
- 在安慰剂组中增加AVCV的趋势被evogliptin抑制.
- 根据18F-NaF PET测量,Evogliptin在48周后显著降低了活性化体积.
结论:
- 这项探索性研究没有证实埃沃格利普丁对大动脉结石化的保护作用.
- 有利的18F-NaF PET结果表明,随着长时间使用埃沃格利普丁,可能会抑制化.
- 需要进行更大规模的确认性试验来验证这些发现并探索更长期的影响.
更多相关视频
09:01Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models
Published on: January 27, 2023
04:30Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
